Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 – Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Introduction 8
2.2 Symptoms 8
2.3 Etiology 8
2.4 Pathophysiology 9
2.5 Diagnosis 9
2.6 Assessment of Disease Severity 10
2.7 Treatment 10
2.7.1 Treatment Algorithm 12
3 Marketed Products 13
3.1 Product Profile 14
3.1.1 Spiriva – Boehringer Ingelheim Pharmaceuticals, Pfizer Inc. 14
3.1.2 Advair Diskus – GlaxoSmithKline 14
3.1.3 Symbicort – AstraZeneca (Co-promotion with Astellas Pharma Inc) 15
3.1.4 Combivent– Boehringer Ingelheim 16
3.1.5 Foradil – Novartis (Co-marketed by Novartis and Schering Corporation) 16
3.1.6 Arcapta/Onbrez Breezhaler – Novartis 17
3.1.7 Daliresp – Nycomed 18
3.1.8 Seebri Breezhaler – Novartis 19
3.1.9 Striverdi Respimat – Boehringer Ingelheim 19
3.1.10 Relvar/Breo – GlaxoSmithKline/Theravance 20
3.1.11 Heat Map – Marketed Products Overview 21
4 COPD Pipeline 23
4.1 Overview 23
4.2 Mechanisms of Action in the Pipeline 25
4.3 Clinical Trials 27
4.3.1 Failure Rate 27
4.3.2 Clinical Trial Duration 33
4.3.3 Clinical Trial Size 35
4.4 Promising Pipeline Molecules 38
4.4.1 Umeclidinium Bromide – GlaxoSmithKline 38
4.4.2 Umeclidinium Bromide + Vilanterol – GlaxoSmithKline/Theravance 38
4.4.3 Vilanterol Trifenatate – GlaxoSmithKline/Theravance 39
4.4.4 Olodaterol + tiotropium – Boehringer Ingelheim 39
4.4.5 TD-4208 – Theravance 40
4.4.6 QVA-149 – Novartis 40
4.4.7 Andolast (CR 2039) – Rottapharm | Madaus 41
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products 41
5 Market Forecast to 2019 47
5.1 Geographical Markets 47
5.1.1 Global Market 49
5.1.2 United States 51
5.1.3 Top Five Countries of Europe 54
5.1.4 Japan 58
5.2 Drivers and Barriers for the COPD Market 60
5.2.1 Drivers 60
5.2.2 Barriers 61
6 Strategic Consolidations 62
6.1 Major Co-development Deals 62
6.1.1 Galapagos Enters into Strategic Alliance with Roche 63
6.1.2 Five Prime Therapeutics Enters into Co-development Agreement with GlaxoSmithKline 63
6.1.3 Forest Labs Enters into Co-development Agreement with Nycomed 63
6.2 Major Licensing Deals 64
6.2.1 Orexo Enters into Licensing Agreement with Ortho-McNeil-Janssen and Janssen Pharmaceutica 67
6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma 68
6.2.3 Evotec Enters into Licensing Agreement with Zhejiang Conba Pharma for EVT 401 68
6.2.4 Halozyme Therapeutics Enters into Licensing Agreement with Intrexon 68
7 Appendix 69
7.1 All Pipeline Drugs by Phase 69
7.1.1 Discovery 69
7.1.2 Pre-clinical 70
7.1.3 Phase I 73
7.1.4 Phase II 74
7.1.5 Phase III 75
7.1.6 Filed 75
7.1.7 Undisclosed 76
7.1.8 Market Forecasts to 2019 76
7.1.9 The United States 76
7.1.10 The UK 77
7.1.11 France 77
7.1.12 Germany 77
7.1.13 Italy 78
7.1.14 Spain 78
7.1.15 Japan 78
7.2 Market Definition 79
7.3 Abbreviations 79
7.4 References 80
7.4.1 References for Pipeline Heat Map 85
7.4.2 References for Marketed Products Heat Map 86
7.5 Methodology 86
7.6 Coverage 87
7.7 Secondary Research 87
7.8 Therapeutic Landscape 87
7.9 Epidemiology-Based Forecasting 88
7.10 Market Size by Geography 89
7.11 Geographical Landscape 90
7.12 Pipeline Analysis 90
7.13 Competitive Landscape 90
7.13.1 Expert Panel Validation 90
7.14 Contact Us 90
7.15 Disclaimer 90